<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994083</url>
  </required_header>
  <id_info>
    <org_study_id>IX-0101</org_study_id>
    <nct_id>NCT01994083</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Oral Doses of IX-01 in Healthy Men</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ixchelsis Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ixchelsis Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of IX-01 after
      multiple doses, and to determine how the body handles IX-01.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Drug Related Adverse Events (AEs) or any Serious AEs</measure>
    <time_frame>Baseline to Day 20 (Estimated up to 3 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of IX-01</measure>
    <time_frame>Pre-dose to 24 hours post dose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUCtau)</measure>
    <time_frame>Pre-dose up to 24 hours post dose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Peak Plasma Concentration (Tmax) of IX-01</measure>
    <time_frame>Pre-dose to 24 hours post dose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life (t1/2) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (Racc) of IX-01 based on AUCtau</measure>
    <time_frame>Pre-dose up to 24 hours post dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (Racc) of IX-01 based on Cmax</measure>
    <time_frame>Pre-dose up to 24 hours post dose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUCt) from Zero to the Time of Last Quantifiable Concentration (AUC(0-t)) of IX-01</measure>
    <time_frame>Pre-dose to 96 hours post dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Concentration (Ctrough) of IX-01</measure>
    <time_frame>Pre-dose on Days 2 to 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Kel) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of IX-01</measure>
    <time_frame>Pre-dose up to 24 hours post dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 6-Î²-hydroxycortisol/cortisol Ratio</measure>
    <time_frame>Pre-dose on Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IX-01 Concentration and Amount Secreted in Semen</measure>
    <time_frame>Between 2 and 4 hours after dosing, on Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IX-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IX-01</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>IX-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (Quetelet index) in the range 18-30

          -  Total body weight greater than (&gt;)50 kilograms (kg) at screening

          -  Able to understand the nature of the trial and any hazards of participating in it

          -  Able to communicate satisfactorily with the investigator and to participate in, and
             comply with the requirements of, the entire trial

          -  Participants and their partners must be willing to use adequate forms of contraception
             and comply with contraception requirements during the trial, and for 4 months after
             the last dose of medication

          -  Must not plan to donate sperm or father a child during the trial, and for 4 months
             after the final dose of medication

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, electrocardiogram (ECG), or
             laboratory values at the screening assessment that could interfere with the objectives
             of the trial or the safety of the participant

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate participation in the trial or make it unnecessarily hazardous

          -  Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory,
             haematological, renal or neurological function, diabetes mellitus, coronary heart
             disease, or history of any psychotic mental illness

          -  Surgery (for example (e.g.) stomach bypass) or medical condition that might affect
             absorption, metabolism or elimination of medicines

          -  Presence or history of severe adverse reaction to any drug

          -  Use of any prescription or over-the-counter medicine during the 14 days before the
             first dose of trial medication, or intention to use any medicine during the trial,
             with the exception of short courses of medication considered by the investigator not
             to interfere with the safety of the participant or the integrity of the trial data
             (such as acetaminophen (paracetamol))

          -  Current use of any herbal remedy or nutritional supplement, or intention to use any
             such product during the study

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months

          -  Previous participation in this trial or any other clinical trial of an oxytocin
             receptor antagonist

          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of
             alcohol weekly or more than 5 cigarettes daily

          -  Blood pressure and heart rate in supine position at the screening examination outside
             the ranges 90-130 millimeters of mercury (mm Hg) systolic, 50-90 mm Hg diastolic;
             heart rate 50-90 beats/minute

          -  Possibility that the participant will not cooperate with the requirements of the
             protocol

          -  Evidence of drug abuse on urine testing

          -  Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1(HIV1) or
             Human Immunodeficiency Virus 2 (HIV2)

          -  Loss of more than 400 milliliters (mL) blood during the 3 months before the trial,
             e.g. as a blood donor

          -  Objection by General Practitioner (GP), on medical grounds, to participant entering
             trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: Ixchelsis@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Ixchelsis Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

